Skip to content

COO Cooper Companies (The)

S&P 500
Weak · 37/100
Health Care
Health Care Supplies

$57.83

▲ 0.7%

Updated Oct 16, 2:25 PM ET

Report Card

COO at a glance — five pillars scored 0–100 from real filed financials.

How the 0–100 rating is calculated
Value
65
Growth
18
Profitability
16
Health
56
Dividends
1

Overall: Weak · 37/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Price — Past Year

▼ Down 5.6% in the year to Jul 6, 2026

Price 50-day average 200-day averageDCF fair value ±15%Source: Yahoo Finance · chart data as of Jul 6, 2026

Key Metrics

Market Cap

$14.47B

P/E

48.16x

Forward P/E (est.)

68.8x

ROE

2.8%

Revenue Growth

6.1%

EPS Growth

-42.6%

Profit Margin

5.6%

FCF Yield

19.1%

Debt / Equity

0.3x

ROIC

5.0%

Interest Coverage

6.49x

Current Ratio

1.27x

Dividend Yield

0.0%

Implied Growth (rev. DCF)

5.8%

Rating Score

37/100

Business Overview

Research

Cooper Companies (The) (COO) is a large-cap company in the Health Care Supplies industry, part of the Health Care sector of the S&P 500, with a market value around $14.47B.

In its latest reported year it generated about $4.09B in revenue and $374.90M in net profit.

Our model rates COO Weak (37/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Economic Moat

Evidence of durable competitive advantage in the filed financials (9 years of history).

Profit margins and economic moats, explained
Wide moat signalsMoat evidence score: 79/100

The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.

Gross margin level100/100

65.9% average over the last 3 years

Gross margin stability85/100

±1.2 pts around 65.2% across 9 years

Revenue durability86/100

grew in 7 of the last 8 year-over-year periods

Free-cash-flow consistency100/100

positive in 9 of 9 years

Return on invested capital0/100

5.0% latest fiscal year

A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.

Technical Analysis (Educational)

Research

Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what COO's chart says today, with each tool explained.

Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. COO trades near $57.83, below its 50-day average ($64.27) and 200-day average ($72.78). Price below both averages is a downtrend — momentum is against buyers for now.

Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.

MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.

Volatility — ATR. Average True Range is the typical daily move. COO's is $1.84 (~3.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.

Support & resistance. In the month to Jul 6, 2026, COO found buyers near $61.09 (support) and sellers near $74.45 (resistance); its 52-week range then was $58.89–$89.83. A decisive break beyond either edge often marks the next move.

Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.

Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.

Revenue Growth

Research
How to read an income statement

4Y CAGR

8.8%

1/4 checks passedRevenue growingRevenue growth beats sector midpointEPS growingEPS growing faster than revenue

Revenue moved from $2.14B in 2017 to $4.09B in 2025, a 8.4% compound annual growth rate. The most recent year grew a steady 6.1% year over year. Slower, mature growth is common for established businesses.

Profitability

Research
What profit margins tell you
1/4 checks passedProfitableNet margin above sector midpointROE above 12%ROIC above 10%

Gross Margin

65.5%

Operating Margin

16.7%

Net Margin

9.2%

ROE

2.8%

Cooper Companies (The) keeps about 5.6% of each sales dollar as net profit, with a 65.5% gross margin and 16.7% operating margin. Return on equity is 2.8% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.

Debt Analysis

Research
4/4 checks passedDebt under 1× equityDebt under 2× equityInterest covered 3×+Short-term bills covered

Total Debt

$2.26B

Net Debt

$2.12B

Net Debt / EBITDA

3.11x

Debt / Equity

0.3x

Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 6.5x, with a current ratio of 1.3x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $2.26B of total debt against $138.80M of cash.

Cash Flow Analysis

Research
3/3 checks passedPositive free cash flowFCF yield above 2%Market expects achievable growth (<8%)

Operating CF

$796.10M

Free Cash Flow

$433.70M

FCF Margin

10.6%

In the latest year Cooper Companies (The) produced about $796.10M of operating cash flow and $433.70M of free cash flow after capital spending. That is a free-cash-flow yield of about 19.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.

Dividend Safety

Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.

What to look for in a dividend stock
SafeSafety score: 70/100

The payout is comfortably covered by cash the business actually generates, with a raise habit behind it.

Dividend yield

0.0%

Per share (latest FY)

$0.03

Total paid (latest FY)

$3.00M

History on record

7 years

Free-cash-flow coverage100/100

dividend uses 1% of free cash flow

Earnings payout ratio100/100

1% of net income paid out

Raise streak0/100

no current raise streak

Cut history100/100

no cuts in the last 7 years on record

Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.

Valuation Analysis

Research
What is a reasonable P/E ratio?
1/4 checks passedPositive earnings (P/E meaningful)P/E below sector's upper bandForward P/E below trailing (earnings growing)Trading below DCF fair value

P/E

48.16x

P/S

3.23x

P/B

1.45x

EV / EBITDA

—

COO trades at 48.2x trailing earnings (about 68.8x on estimated forward earnings), 3.2x sales, and 1.4x book value. Reverse-engineering today's price implies the market expects roughly 5.8% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.

DCF Fair Value (Educational)

A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.

How this DCF estimate is calculated

DCF fair value / share

$42.96

Current price

$57.83

-26% · Above fair-value estimate

Starting FCF (latest 10-K)

$433.70M

Growth, years 1–5

6.1%

Fade to terminal, years 6–10

2.5%

Discount rate

9.0%

PV of 10-yr free cash flow$3.67B
PV of terminal value$4.71B
Estimated equity value$8.38B
Shares outstanding195M

Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.

Metrics vs. Sector Range

Where COO sits versus the Health Care companies we cover.

TTM P/E
48.2xExpensive
Forward P/E
68.8xExpensive
P/S ratio
3.2xFair
Revenue growth
6.1%Average
EPS growth
-42.6%Weak
Gross margin
65.5%Average
Net margin
5.6%Weak
ROE
2.8%Weak

Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How COO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.

Among the 83 rated Health Care companies we cover, COO ranks #66 by our overall rating. It trades at a premium versus the sector on earnings (48.2x P/E vs. 26.1x median) with a lower return on equity (2.8% vs. 14.1%) and slower revenue growth (6.1% vs. 7.6%).

P/E vs sector

48.2x

median 26.1x

ROE vs sector

2.8%

median 14.1%

Growth vs sector

6.1%

median 7.6%

Sector rank

#66

of 83 rated

CompanyP/ERev Gr.Rating
COOThis stock48.2x6.1%Weak· 37
ALGN24.6x2.9%Neutral· 53
WST46.3x11.2%Neutral· 56
DVA15.5x6.7%Neutral· 53
RDY27.3x3.2%Weak· 39
SOLV10.4x-0.6%Favorable· 65
GMAB20.9x20.7%Favorable· 62
RVTY71.4x4.8%Weak· 30
Health Care median26.1x7.6%52/100

Valuation vs. quality map

sector medianALGNWSTDVARDYSOLVGMABRVTYCOOP/E — cheaper ←→ pricierROE — more profitable ↑

The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.

Compare side by side

Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.

5-Year Projection Model

Project revenue → earnings → price. Edit the assumptions to build your own case.

What drives this projection, and its limits

2030 scenario price range (Base Case)

$57.12 – $94.54

vs. $57.83 today · implied CAGR -0% – 10%

Metric20262027202820292030
Revenue$4.34B$4.60B$4.87B$5.17B$5.48B
Net income$390.41M$413.84M$438.67M$464.99M$492.89M
EPS$1.56$1.65$1.75$1.86$1.97
Share price (low)$45.25$47.96$50.84$53.89$57.12
Share price (high)$74.89$79.38$84.14$89.19$94.54
CAGR (low–high)-22% / 29%-9% / 17%-4% / 13%-2% / 11%-0% / 10%

Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions.

Bull Case

The case for COO:

  • Healthy free-cash-flow yield (~19.1%) funds buybacks and dividends.
  • A conservative balance sheet (debt/equity 0.3x) lowers risk.

Bear Case

The case against COO:

  • A rich 48.2x earnings multiple prices in a lot of growth.
  • Our model's overall read is Weak (37/100).

Key Risks

Research

Valuation risk — at 48.2x earnings, disappointing results could compress the multiple.

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis

Research

On balance, the fundamentals screen weakly: Cooper Companies (The) is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 48.2x earnings, which our model scores Weak (37/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

Analyst Ratings

What 23 Wall Street analysts covering COO recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.

Buy
consensus · score 3.8 / 5 across 23 analysts
Strong Buy 6Buy 7Hold 10Sell 0Strong Sell 0

Latest SEC Filings

COO's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K

In the Idea Lab

COO — frequently asked questions

Is COO a good stock to buy?

We don't give buy or sell advice. Our model rates Cooper Companies (The) Weak (37/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.

What is COO's rating on The Stocks School?

Cooper Companies (The) currently scores 37/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.

How our ratings work →
Where does COO's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from Cooper Companies (The)'s SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for COO calculated?

It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.

Is this COO analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell COO. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.